Nat Med: Bloodborne tumor mutational burden as a biomarker for atezolizumab therapy in non-small cell lung cancer

Atezolizumab monotherapy has good efficacy in the first-line treatment of patients with EGFR/ALK wild-type squamous or non-squamous locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express highly programmed Death Ligand 1 (PD-L1)

In a study published today in the top medical journal Nature Medicine to prospectively assess blood TMB (bTMB), researchers conducted the B-F1RST trial (NCT02848651), an open-label 2 Phase III clinical trial evaluating bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n=152)

The study's co-primary endpoints were investigator-assessed objective response rate (ORR) for RECIST version 1.

The investigator-assessed PFS of bTMB≥16 group and bTMB<16 group was not statistically significant

Thus, the development of bTMB as a predictive, stand-alone immunotherapy biomarker or in combination with other biomarkers requires further research and optimized analysis

Original source:

Edward S.